Evaluation of recurrence score and traditional clinicopathologic assessments in a large ER-positive, lymph node-negative patient cohort.
2011; Lippincott Williams & Wilkins; Volume: 29; Issue: 15_suppl Linguagem: Inglês
10.1200/jco.2011.29.15_suppl.632
ISSN1527-7755
AutoresN. Liebermann, F. L. Baehner, L. Soussan-Gutman, S. Klang, Carl Yoshizawa, S. Shak, Nava Siegelmann‐Danieli,
Tópico(s)Advanced Breast Cancer Therapies
Resumo632 Background: The Recurrence Score (RS) assay provides prognostic and predictive information for estrogen receptor positive (ER+) breast cancer. In a large cohort of ER+, HER2-, lymph node negative (LN-) patients (pts), the distribution of RS and RS groups, within categories of age, tumor size, grade, and joint categories (e.g., size versus grade) were examined. Methods: 2,097 pts from Clalit Health Services and 484 from Maccabi Health Services in Tel Aviv, Israel, had RS assay ordered between 1/2008 and 6/2010. 1864 were LN-, ER+, HER2- (LN- grade 3 tumors of MHS pts required to be < 2 cm). Pt age, tumor size and grade were obtained for 100%, 99% and 82% of cases. Distributions of RS were compared among categories of the clinicopathologic factors and Spearman correlation coefficients (and 95% confidence intervals) were calculated to assess the association between them. Results: 99.3% were female. Age distributions were: 23-40yo, 3.2%; 40-49yo , 16.5%; 50 - 59yo, 30.4%; 60-69yo, 32.8%; 70-85yo, 17.1%. Tumor sizes were: 2-3cm, 17.3%; >3cm, 4.5%. By grade: 1, 18.1%; 2, 63%; 3, 18.9%. 79.7% were ductal and 12.5% lobular. 81.9% were IHC PR+. Spearman cc’s (and 95% CI) for continuous RS with standard metrics: age, -0.09 (-0.13,-0.04); tumor size (cm), 0.07 (0.02,0.12); tumor grade, 0.33 (0.28,0.37). Pts 2 cm 30.7% had high RS. 1.4% of grade 1 tumors had high RS and 30.7% had intermediate RS while 22.8 % of grade 3 tumors had low RS. 7.5% of PR+ tumors had high RS and 20.1% of PR- tumors had low RS. Joint categories will be presented. Conclusions: There is a range of RS biology across pt age, tumor size, grade. The RS can’t be predicted by clinicopathologic variables. Characteristic Value Low (RS<18) Int (RS 18-30) High (RS≥31) Age (years) 2 29 (9.5%) 183 (59.8%) 94 (30.7%) Tumor grade 1 188 (67.9%) 85 (30.7%) 4 (1.4%) 2 507 (52.6%) 366 (38.0%) 91 (9.4%) 3 66 (22.8%) 132 (45.7%) 91 (31.5%) PR by IHC Neg 67 (20.1%) 176 (52.9%) 90 (27.0%) Pos 860 (57.1%) 533 (35.4%) 113 (7.5%)
Referência(s)